These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 9816155)
1. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155 [TBL] [Abstract][Full Text] [Related]
2. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Vanhoefer U; Yin MB; Harstrick A; Seeber S; Rustum YM Biochem Pharmacol; 1997 Mar; 53(6):801-9. PubMed ID: 9113101 [TBL] [Abstract][Full Text] [Related]
3. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653 [TBL] [Abstract][Full Text] [Related]
4. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387 [TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Kramer RA; Greene K; Ahmad S; Vistica DT Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359 [TBL] [Abstract][Full Text] [Related]
6. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice. Soble MJ; Dorr RT Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633 [TBL] [Abstract][Full Text] [Related]
7. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Slovak ML; Ho JP; Bhardwaj G; Kurz EU; Deeley RG; Cole SP Cancer Res; 1993 Jul; 53(14):3221-5. PubMed ID: 8391919 [TBL] [Abstract][Full Text] [Related]
8. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. Chen G; Zeller WJ Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476 [TBL] [Abstract][Full Text] [Related]
10. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Vanhoefer U; Cao S; Minderman H; Tóth K; Scheper RJ; Slovak ML; Rustum YM Clin Cancer Res; 1996 Feb; 2(2):369-77. PubMed ID: 9816180 [TBL] [Abstract][Full Text] [Related]
11. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Majumder S; Dutta P; Mookerjee A; Choudhuri SK Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015 [TBL] [Abstract][Full Text] [Related]
12. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo. Caffrey PB; Zhang Y; Frenkel GD Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503 [TBL] [Abstract][Full Text] [Related]
13. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Minderman H; Vanhoefer U; Toth K; Yin MB; Minderman MD; Wrzosek C; Slovak ML; Rustum YM Cytometry; 1996 Sep; 25(1):14-20. PubMed ID: 8875050 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Wu XX; Ogawa O; Kakehi Y Int J Oncol; 2004 Jun; 24(6):1489-97. PubMed ID: 15138592 [TBL] [Abstract][Full Text] [Related]
15. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow. Ono K; Shrieve DC J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662 [TBL] [Abstract][Full Text] [Related]
16. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067. Xu BH; Singh SV Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304 [TBL] [Abstract][Full Text] [Related]
18. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole. Desai PB; Duan J; Sridhar R; Damle BD Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648 [TBL] [Abstract][Full Text] [Related]
19. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437 [TBL] [Abstract][Full Text] [Related]
20. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Dusre L; Mimnaugh EG; Myers CE; Sinha BK Cancer Res; 1989 Feb; 49(3):511-5. PubMed ID: 2535960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]